| Literature DB >> 30003812 |
Yme U van der Velden1, Julien Villaudy1,2, Esther Siteur-van Rijnstra3, Cynthia A van der Linden1,3, Esmay Frankin1, Kees Weijer3, Edith Schermer1, Monique A Vink1, Ben Berkhout1, Rogier W Sanders1,4, Marit J van Gils1.
Abstract
Broadly neutralizing antibodies (bNAbs) such as PGDM1400 show promise as prophylactic and therapeutic agents against HIV-1. Human immune system mice were passively immunized with different doses of PGDM1400 and challenged 24 h later with a high dose of HIV-1JRCSF. We found that PGDM1400 provided protection against HIV-1 challenge in a concentration dependent manner and that the protective concentration in blood was ∼75-fold higher than the in vitro 50% inhibitory concentration. The results demonstrate that PGDM1400 might be a promising component of strategies to prevent HIV-1 infection and provide support for the pursuit of vaccines that induce PGDM1400-like bNAbs.Entities:
Keywords: HIV-1; PGDM1400; broadly neutralizing antibody; human immune system mouse; prophylactic agent
Mesh：
Substances：
Year: 2018 PMID： 30003812 DOI： 10.1089/AID.2018.0114
Source DB: PubMed Journal: AIDS Res Hum Retroviruses ISSN： 0889-2229 Impact factor: 2.205